The stock of Fate Therapeutics Inc. (NASDAQ: FATE) has decreased by -6.78 when compared to last closing price of 2.36. Despite this, the company has experienced a -11.29% fall in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-09-07 that Fate Therapeutics (FATE) reported earnings 30 days ago. What’s next for the stock?
Is It Worth Investing in Fate Therapeutics Inc. (NASDAQ: FATE) Right Now?
The 36-month beta value for FATE is also noteworthy at 1.47. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 14 rating it as “hold,” and 0 rating it as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price estimated by analysts for FATE is $7.38, which is $5.24 above than the current price. The public float for FATE is 97.14M, and at present, short sellers hold a 28.45% of that float. The average trading volume of FATE on September 18, 2023 was 2.17M shares.
FATE’s Market Performance
FATE stock saw a decrease of -11.29% in the past week, with a monthly decline of -21.15% and a quarterly a decrease of -62.13%. The volatility ratio for the week is 7.02%, and the volatility levels for the last 30 days are 6.92% for Fate Therapeutics Inc. (FATE). The simple moving average for the past 20 days is -15.66% for FATE’s stock, with a -65.47% simple moving average for the past 200 days.
Analysts’ Opinion of FATE
Many brokerage firms have already submitted their reports for FATE stocks, with Wells Fargo repeating the rating for FATE by listing it as a “Equal Weight.” The predicted price for FATE in the upcoming period, according to Wells Fargo is $6 based on the research report published on March 27, 2023 of the current year 2023.
FATE Trading at -37.10% from the 50-Day Moving Average
After a stumble in the market that brought FATE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.94% of loss for the given period.
Volatility was left at 6.92%, however, over the last 30 days, the volatility rate increased by 7.02%, as shares sank -20.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.89% lower at present.
During the last 5 trading sessions, FATE fell by -11.29%, which changed the moving average for the period of 200-days by -88.58% in comparison to the 20-day moving average, which settled at $2.58. In addition, Fate Therapeutics Inc. saw -78.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FATE starting from Dulac Edward J III, who sale 4,718 shares at the price of $2.80 back on Aug 18. After this action, Dulac Edward J III now owns 119,570 shares of Fate Therapeutics Inc., valued at $13,210 using the latest closing price.
Xu Yuan, the Director of Fate Therapeutics Inc., sale 632 shares at $3.71 during a trade that took place back on Aug 04, which means that Xu Yuan is holding 9,302 shares at $2,345 based on the most recent closing price.
Stock Fundamentals for FATE
Current profitability levels for the company are sitting at:
- -320.23 for the present operating margin
- +85.71 for the gross margin
The net margin for Fate Therapeutics Inc. stands at -292.55. The total capital return value is set at -44.47, while invested capital returns managed to touch -40.96. Equity return is now at value -44.10, with -31.70 for asset returns.
Based on Fate Therapeutics Inc. (FATE), the company’s capital structure generated 22.59 points at debt to equity in total, while total debt to capital is 18.43. Total debt to assets is 15.50, with long-term debt to equity ratio resting at 21.43. Finally, the long-term debt to capital ratio is 17.48.
When we switch over and look at the enterprise to sales, we see a ratio of -0.92, with the company’s debt to enterprise value settled at 0.17. The receivables turnover for the company is 4.08 and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.40.
Conclusion
In summary, Fate Therapeutics Inc. (FATE) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
